Fig. 3 | Scientific Reports

Fig. 3

From: Efficacy and safety of RC48 alone or combined with PD-1 inhibitors in high-risk non-muscle invasive bladder cancer

Fig. 3The alternative text for this image may have been generated using AI.

Radiographic imaging and HER2 immunohistochemical (IHC) staining of Patient 20. The left panel shows the bladder tumor and HER2 expressing before treatment. The right panel shows the bladder tumor after 4 cycles of RC48 combined with PD-1 inhibitors and the status of HER2 expressing after radical cystectomy.

Back to article page